(Albany, USA) – DelveInsight’s “Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of the CAH landscape, covering current treatment practices, emerging therapies, market share of individual drugs, and projected market size from 2020 to 2034 across the 7MM—the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The Congenital Adrenal Hyperplasia report evaluates treatment algorithms, market drivers, barriers, and unmet medical needs, offering stakeholders actionable insights to navigate opportunities in the CAH therapeutics space.
Request a sample report @ Congenital Adrenal Hyperplasia Treatment Market
Key Insights from the CAH Market Report
- In 2023, the total CAH market size in the 7MM exceeded USD 20 million, with a projected CAGR of ~40% through 2034.
- The total diagnosed prevalent cases of CAH in 2021 were over 73K, with the highest incidence observed in the US.
- Leading companies developing novel CAH therapies include Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc., Neurocrine Biosciences, Lundbeck, BridgeBio, and Spruce Biosciences.
- Promising pipeline therapies include CRN04894, Chronocort, EFMODY, AAV BBP-631, Crinecerfont, Tildacerfont, ATUMELNANT, BBP-631, and Lu AG13909.
- Neurocrine Biosciences reported positive Phase 3 CAHtalyst™ trial outcomes for CRENESSITY™ (crinecerfont) in both pediatric and adult CAH patients, demonstrating glucocorticoid dose reductions and improved hormone regulation.
- Crinetics Pharmaceuticals announced positive Phase 2 results for atumelnant, an ACTH receptor antagonist for classic CAH and ACTH-dependent Cushing’s syndrome.
- BridgeBio Pharma presented topline results from the Phase 1/2 BBP-631 AAV gene therapy trial, targeting CAH.
- Spruce Biosciences plans to release topline results for tildacerfont studies (CAHmelia-204 and CAHptain-205) in late 2024.
Discover which therapies are poised to capture market share @ Congenital Adrenal Hyperplasia Market Report
Congenital Adrenal Hyperplasia Overview
CAH is a group of inherited disorders affecting adrenal hormone production, most commonly due to 21-hydroxylase deficiency, leading to cortisol and aldosterone deficiency and excess androgen production. CAH is classified into:
- Classic CAH: Diagnosed in infancy/early childhood; includes salt-wasting and simple virilizing forms.
- Non-classic CAH: Milder, late-onset form; may present in adolescence/adulthood.
Symptoms vary by severity and type and include ambiguous genitalia in newborn females, early puberty, rapid childhood growth, and infertility. Diagnosis involves hormonal and genetic testing, while treatment generally requires lifelong hormone replacement therapy.
Learn more about CAH treatment guidelines @ Congenital Adrenal Hyperplasia Management
CAH Epidemiology and Market Segmentation
- Age-specific cases, mutation-specific cases, and type-specific (classic vs. non-classic) prevalence in the 7MM
- The US leads in diagnosed CAH cases, with over 9K age-specific cases.
CAH Treatment and Pipeline Therapies
Current treatments focus on hormone replacement therapy to manage cortisol deficiency and control androgen excess.
- Glucocorticoids (oral hydrocortisone) remain standard, with dosing adjusted by age and severity.
- Mineralocorticoids (9α-fludrocortisone) and sodium supplements are essential for salt-wasting CAH in newborns and infants.
Pipeline therapies under investigation include:
- CRN04894 (Crinetics Pharmaceuticals Inc.)
- Chronocort (Diurnal Limited)
- AAV BBP-631 (Adrenas Therapeutics Inc.)
- Crinecerfont (Neurocrine Biosciences)
- Tildacerfont (Spruce Biosciences)
Explore drugs in development @ Congenital Adrenal Hyperplasia Clinical Trials
Congenital Adrenal Hyperplasia Market Dynamics and Opportunities
The Congenital Adrenal Hyperplasia market is evolving with:
- Enhanced newborn screening programs enabling early detection.
- Ongoing trials for gene therapies, selective CRF1 receptor inhibitors, and ACAT-1 inhibitors.
- Novel treatment approaches to manage long-term glucocorticoid side effects.
Challenges include delayed diagnosis of non-classic CAH, misdiagnosis, high costs of gene therapies, and access/reimbursement hurdles, which may limit market growth.
Congenital Adrenal Hyperplasia Key Metrics
- Study Period: 2020–2034
- Coverage: 7MM
- 2023 Market Size: USD 20 Million
- Major Companies: Crinetics Pharmaceuticals Inc., Diurnal Limited, Adrenas Therapeutics Inc., Neurocrine Biosciences, Lundbeck, BridgeBio, Spruce Biosciences, and others
- Pipeline Therapies: CRN04894, Chronocort, AAV BBP-631, Crinecerfont, Tildacerfont, and others
Stay updated on emerging Congenital Adrenal Hyperplasia therapies and market trends @ Drugs for Congenital Adrenal Hyperplasia Treatment
